Tripos Amends Chemistry Collaboration with Pfizer
Tripos, Inc. announced an amendment to its strategic collaboration with Pfizer Inc. for the design, synthesis and purification of druglike compounds. Tripos will reduce file enrichment activities with Pfizer, but partially offsetting this reduction, Tripos will engage in new work for Pfizer in the areas of hit follow-up and large library production, the next steps in the drug discovery process that follow directly from screening library compounds. Terms of the amended agreement include a reduction in the remaining work to be done under this four-year, $100 million collaboration, resulting in a decrease in the total contract value of approximately 10 percent, with the bulk of the reduction occurring in 2005.
Other agreements between Tripos and Pfizer, including computational chemistry and laboratory research system development, are not impacted by these revisions.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.